Robert Rönn
Senior Vice President & Head, Research & Development Orexo
Robert Rönn, PhD, is SVP and Head of R&D at Orexo AB, where he leads the development of innovative drug delivery technologies and pharmaceutical products. He has extensive experience across drug development, analytical sciences, formulation development, regulatory strategy, and lifecycle management. Robert has played a key role in advancing Orexo’s AmorphOX® powder-based drug delivery platform, with a particular focus on nasal delivery of small molecules, peptides, biologics, and vaccines. Throughout his career, he has led multidisciplinary R&D teams and strategic innovation programs spanning preclinical development through commercialization.
Seminars
Thursday 4th February 2027
Advancing Powder-Based Nasal Products: Leveraging Stability & Rapid Absorption to Unlock Next-Generation Intranasal Therapies
9:00 am
- Explore how powder formulations can overcome stability limitations associated with traditional liquid products while simplifying storage, transportation, and long-term product performance
- Understand how formulation and device design influence deposition, absorption, and pharmacodynamic performance, including lessons learned from clinical development
- Learn how developers are overcoming regulatory, manufacturing, and product development challenges when advancing powder-based intranasal products toward commercialization
